Graham G M, Guarini L, Moulton T A, Datta S, Ferrone S, Giacomini P, Kerbel R S, Fisher P B
Department of Neurosurgery, Columbia University, College of Physicians and Surgeons, New York, New York 10032.
Cancer Immunol Immunother. 1991;32(6):382-90. doi: 10.1007/BF01741333.
Administration of interferon as a single therapeutic regimen in cancer patients with various neoplasias has had only limited efficacy in ameliorating the negative clinical course of their disease. In the present study, we have evaluated the effect of recombinant human fibroblast (IFN beta) and immune (IFN gamma) interferon, alone and in combination, on growth, differentiation and the expression of class I and II histocompatibility locus antigens (HLA) and melanoma-associated antigens on the human melanoma cell line H0-1. The effect of combinations of interferons on the antigenic profile of human melanoma cells displaying different organ colonization and spontaneous metastatic potential in athymic nude mice was also determined. H0-1 cells were more sensitive to the antiproliferative activity of IFN beta than to IFN gamma and the combination of interferons resulted in a potentiation of growth suppression. The antiproliferative effect of both interferons was greater in later-passage than in earlier-passage H0-1 cells, possibly reflecting alterations in the evolving tumor cell population as a result of long-term in vitro propagation and/or the selective outgrowth of cells with an increased growth rate. The enhanced growth suppression observed in H0-1 cells treated with the combination of IFN beta plus IFN gamma was not associated with a significant increase in the level of melanin, a marker of melanoma differentiation, above that observed with either interferon used alone. IFN beta and IFN gamma differentially modulated the expression of class I and II HLA and melanoma-associated antigens in H0-1 cells and a series of melanoma cells with different organ colonization and metastatic potential, including MeWo, MeM 50-10, MeM 50-17, 3S5 and 70W. No consistent potentiation or antagonism in the expression of any specific antigen was observed in any of the melanoma cell lines exposed to the combination of interferons. The present study demonstrates that the combination of IFN beta plus IFN gamma can potentiate growth suppression in H0-1 human melanoma cells and that this effect is not associated with an increase in differentiation or a potentiation in antigenic modulation. In addition, no direct correlation between the expression of any specific antigen or its modulation by IFN beta or IFN gamma, alone or in combination, and organ colonization and metastatic potential in nude mice was observed in the different melanoma cell lines.
在患有各种肿瘤的癌症患者中,将干扰素作为单一治疗方案使用,在改善其疾病的负面临床病程方面效果有限。在本研究中,我们评估了重组人成纤维细胞干扰素(IFN-β)和免疫干扰素(IFN-γ)单独及联合使用对人黑色素瘤细胞系H0-1的生长、分化以及I类和II类组织相容性位点抗原(HLA)和黑色素瘤相关抗原表达的影响。还确定了干扰素组合对在无胸腺裸鼠中表现出不同器官定植和自发转移潜能的人黑色素瘤细胞抗原谱的影响。H0-1细胞对IFN-β的抗增殖活性比对IFN-γ更敏感,并且干扰素联合使用导致生长抑制作用增强。两种干扰素的抗增殖作用在传代后期的H0-1细胞中比在传代早期的细胞中更强,这可能反映了由于长期体外传代导致的不断演变的肿瘤细胞群体的变化和/或生长速率增加的细胞的选择性生长。在用IFN-β加IFN-γ联合处理的H0-1细胞中观察到的增强的生长抑制与黑色素(黑色素瘤分化的标志物)水平的显著增加无关,黑色素水平的增加不高于单独使用任何一种干扰素时观察到的水平。IFN-β和IFN-γ在H0-1细胞以及一系列具有不同器官定植和转移潜能的黑色素瘤细胞(包括MeWo、MeM 50-10、MeM 50-17、3S5和70W)中对I类和II类HLA以及黑色素瘤相关抗原的表达进行了不同的调节。在任何暴露于干扰素组合的黑色素瘤细胞系中,均未观察到任何特定抗原表达的一致增强或拮抗作用。本研究表明,IFN-β加IFN-γ的组合可增强H0-1人黑色素瘤细胞的生长抑制,并且这种作用与分化增加或抗原调节增强无关。此外,在不同的黑色素瘤细胞系中,未观察到任何特定抗原的表达或其被IFN-β或IFN-γ单独或联合调节与裸鼠中的器官定植和转移潜能之间存在直接相关性。